Evidence map›Paper›PMID 30028342›Full record

ReviewNeural regeneration research2018

Stem cells: a promising candidate to treat neurological disorders.

Chang-Geng Song, Yi-Zhe Zhang, Hai-Ning Wu, Xiu-Li Cao, Chen-Jun Guo, Yong-Qiang Li, Min-Hua Zheng, Hua Han

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neural regeneration research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chang-Geng SongDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Yi-Zhe ZhangDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Hai-Ning WuDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Xiu-Li CaoDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Chen-Jun GuoDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Yong-Qiang LiDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Min-Hua ZhengDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Hua HanDepartment of Medical Genetics and Developmental Biology, Fourth Military Medical University; Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurologic impairments are usually irreversible as a result of limited regeneration in the central nervous system. Therefore, based on the regenerative capacity of stem cells, transplantation therapies of various stem cells have been tested in basic research and preclinical trials, and some have shown great prospects. This manuscript overviews the cellular and molecular characteristics of embryonic stem cells, induced pluripotent stem cells, neural stem cells, retinal stem/progenitor cells, mesenchymal stem/stromal cells, and their derivatives in vivo and in vitro as sources for regenerative therapy. These cells have all been considered as candidates to treat several major neurological disorders and diseases, owing to their self-renewal capacity, multi-directional differentiation, neurotrophic properties, and immune modulation effects. We also review representative basic research and recent clinical trials using stem cells for neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and age-related macular degeneration, as well as traumatic brain injury and glioblastoma. In spite of a few unsuccessful cases, risks of tumorigenicity, and ethical concerns, most results of animal experiments and clinical trials demonstrate efficacious therapeutic effects of stem cells in the treatment of nervous system disease. In summary, these emerging findings in regenerative medicine are likely to contribute to breakthroughs in the treatment of neurological disorders. Thus, stem cells are a promising candidate for the treatment of nervous system diseases.

Indexed as

animal experimentclinical trialnerve regenerationnervous systemneural regenerationneurodegenerative diseaseneurological disordersregenerative medicinestem cellsstem cell therapytransplantation

Identifiers

PMID30028342
PMCPMC6065243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.